Us Bancorp \De\ Crinetics Pharmaceuticals, Inc. Transaction History

Us Bancorp \De\

$75.6 Billion
Q4 2024

A detailed history of Us Bancorp \De\ transactions in Crinetics Pharmaceuticals, Inc. stock. As of the latest transaction made, Us Bancorp \De\ holds 6,312 shares of CRNX stock, worth $233,417. This represents 0.0% of its overall portfolio holdings.

Number of Shares

6,312

Previous 11,488 45.06%

Holding current value

$233,417

Previous $586,000 45.05%

% of portfolio

0.0%

Previous 0.0%

14 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 05, 2025	SELL	$50.66 - $60.69 $262,216 - $314,131	-5,176 Reduced 45.06%	6,312 $322,000
Q3 2024 Oct 28, 2024	BUY	$43.83 - $54.98 $16,348 - $20,507	373 Added 3.36%	11,488 $586,000
Q2 2024 Aug 06, 2024	BUY	$42.12 - $51.91 $292,818 - $360,878	6,952 Added 166.99%	11,115 $497,000
Q1 2024 May 07, 2024	BUY	$34.76 - $46.81 $137,580 - $185,273	3,958 Added 1930.73%	4,163 $194,000
Q4 2023 Feb 09, 2024	SELL	$25.62 - $37.07 $225,097 - $325,697	-8,786 Reduced 97.72%	205 $7,000
Q3 2023 Nov 03, 2023	BUY	$15.97 - $30.59 $142,580 - $273,107	8,928 Added 14171.43%	8,991 $267,000
Q2 2023 Aug 09, 2023	SELL	$15.73 - $23.6 $1,368 - $2,053	-87 Reduced 58.0%	63 $1,000
Q1 2023 May 09, 2023	BUY	$15.31 - $21.1 $1,331 - $1,835	87 Added 138.1%	150 $2,000
Q4 2022 Feb 13, 2023	SELL	$15.49 - $19.05 $278 - $342	-18 Reduced 22.22%	63 $1,000
Q3 2022 Oct 27, 2022	BUY	$18.11 - $22.37 $325 - $402	18 Added 28.57%	81 $2,000
Q3 2021 Nov 10, 2021	SELL	$16.88 - $25.23 $2,160 - $3,229	-128 Reduced 67.02%	63 $1,000
Q2 2021 Aug 05, 2021	BUY	$15.9 - $21.15 $1,224 - $1,628	77 Added 67.54%	191 $4,000
Q1 2021 Apr 28, 2021	BUY	$13.3 - $17.55 $678 - $895	51 Added 80.95%	114 $2,000
Q4 2020 Feb 04, 2021	BUY	$12.08 - $17.46 $761 - $1,099	63 New	63 $1,000

Others Institutions Holding CRNX

# of Institutions

245

Shares Held

80.1M

Call Options Held

23.3K

Put Options Held

44.3K

View Full List

About Crinetics Pharmaceuticals, Inc.

Ticker CRNX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 53,752,800
Market Cap $1.99B
Description
Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist that has completed phase III ...

More about CRNX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Us Bancorp \De\, based on Form 13F filings with the SEC.

News

Stay updated on Us Bancorp \De\ with notifications on news.

Account